The pooled OR indicated that MGMT promoter methylation was significantly linked to pathological types in ovarian cancer (OR = 0.29, 95% CI = 0.14–0.59, p = .001), including five studies with 185 serous cancer and 155 nonserous cancer patients. Here, MGMT is linked to ovarian cancer.